Search Results

Spotlight On Mantle Cell Lymphoma

Marginal Zone Lymphoma (MZL)

Information for Patients with Aggressive Lymphomas

Living with Cutaneous T-cell Lymphoma

Mantle cell lymphoma (MCL)

Lymphoma Research Funded by LLS

Working for The Leukemia & Lymphoma Society

Hodgkin Lymphoma 3D Model

.model-icon-key-mobile{ display:none;} @media only screen and (max-width: 767px) { .model-icon-key-desktop{ display: none;} .model-icon-key-mobile{ display: block;} }

This model contains the following chapters. Click the "Interact in 3D" button to begin.

• Healthy Bone Marrow
• Normal Blood Cell Production
• Proliferation of Cells and the Crowding Out of Normal Cells
• Signs and Symptoms

 

Central Nervous System (CNS) Lymphoma

General Information

Central nervous system lymphoma is a rare non-Hodgkin lymphoma in which malignant (cancer) cells from lymph tissue form in the brain and/or spinal cord (primary CNS) or spread from other parts of the body to the brain and/or spinal cord (secondary CNS). Because the eye is so close to the brain, primary CNS lymphoma can also start in the eye (called ocular lymphoma). The cancer can also involve the spinal fluid that bathes the spinal cord and brain. This is called leptomeningeal lymphoma. Both primary and secondary CNS lymphomas are rare diseases.

Bispecific antibody-based frontline therapy for follicular lymphoma

We are conducting a clinical trial testing a novel form of immunotherapy, called a bispecific antibody, as part of initial treatment for patients with follicular lymphoma. The goal of the trial is two-fold: 1) to establish a highly effective, chemotherapy-free treatment option for patients with follicular lymphoma, and 2) to establish predictors of response and toxicity that can guide treatment decisions for future patients with follicular lymphoma.

Brentuximab vedotin

Brentuximab vedotin is FDA approved for the treatment of:

Towards Risk-Adapted Therapeutic Strategies in CNS Lymphoma

This project will significantly advance the treatment and prevention of CNS lymphomas in two key areas. One, we will further develop and validate candidate genomic biomarkers that identify high risk disease and that are useful in risk stratification in future clinical investigations in primary CNS lymphoma.

Overcoming ibrutinib resistance in mantle cell lymphoma

Mantle cell lymphoma (MCL) is an aggressive blood cancer which affects about 3,000 individuals in the United States annually. Despite advances of novel therapies in blood cancers, MCL remains incurable, and patients ultimately succumb to disease. We seek to evaluate longitudinal samples from patients with MCL treated with novel therapies to understand the mechanisms of drug resistance. We identify novel targets, with a particular focus on protein turnover pathways, to overcome drug resistance and improve survival of patients with MCL.

Lisocabtagene maraleucel

Lisocabtagene maraleucel is indicated for the treatment of

Epcoritamab-bysp

Epcoritamab-bysp is indicated for the treatment of 

• Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma 
  • Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy
• Follicular Lymphoma 
  • Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy 

Axicabtagene ciloleucel

Axicabtagene ciloleucel is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:

What Is Blood Cancer?

Reviewed by Gwen Nichols, MD, EVP and Chief Medical Officer at The Leukemia & Lymphoma Society

Highlights from ASH 2021

The American Society of Hematology (ASH) annual meeting is the premier scientific forum on blood cancers. More than 5,000 potentially game-changing research abstracts were presented at this year’s meeting. Every year, I come away with a strengthened sense of hope about new treatments on the horizon and renewed pride in The Leukemia & Lymphoma Society’s (LLS) role in supporting so many of them.

Rituximab and hyaluronidase human

Rituximab and hyaluronidase human is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with:

Restoring lymphoma immunosurveillance by combined EZH2 inhibition and immunotherapy

The project builds on evidence that mutations leading to persistent EZH2 activation drive germinal center B-cell lymphomagenesis by disrupting T-cell surveillance, and will test the hypothesis that EZH2 inhibition synergizes with immune checkpoint blockade and/or co-stimulation to eradicate these diseases. These results will provide the rationale for clinical development of precision-medicine immune-epigenetic combination therapies for lymphomas where these mechanisms are specifically altered.

Diagnosed with a Blood Cancer? Important Questions You Might Not Think to Ask

What is my actual diagnosis? Find out your exact diagnosis. Ask your doctor to write down the exact name of your sub-type and take the paper with you. For example, knowing you have “a B-cell lymphoma” isn’t good enough. Follicular and diffuse large B-cell are both B-cell lymphomas but with very different prognoses and treatment plans. Leukemia also has different sub-types. Knowing your specific sub-type helps you understand what disease you are dealing with, how aggressive it is, and what to expect from treatment.

Attention Hodgkin Lymphoma Patients and Caregivers!